Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREAK-2: Dabrafenib in BRAF Mutant Metastatic Melanoma
NCT01153763Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of dabrafenib + trametinib in melanoma, sponsored by GSK. Started Aug 2010; status: completed.
02
Drugs
dabrafenib + trametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01153763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01153763.